New NIST guide focuses on user-centered design for EHRs

A new guide from the National Institute of Standards and Technology (NIST) aims to make EHRs more usable and safer.

The guide outlines ways to identify critical areas of risk and methods for improving user-centered design. The organization presents an "empirical rationale" to drive standardized patient safety-focused usability guidelines and offers recommendations to eliminate "never events" and associated patient harm by working proactively to mitigate root causes of EHR use errors caused by suboptimal design and implementation.

"The ultimate goal is to drive and empower effective and safe human performance in the use of EHRs," NIST officials wrote. 

The researchers used five different methods of data collection and found three major problems associated with EHRs causing suboptimal and unsafe patient care: identification of information, consistency of information; integrity of information. Recurring issues include unintended actions; the likelihood of use errors; and a "high level" of user frustration.

"Ultimately, the data from this study demonstrate that during safety-critical tasks and times, patient safety is negatively affected, in part because mistakes and critical use errors occur more frequently and because users are highly frustrated, and thus more likely to employ workarounds, such as relying upon supplemental artifacts, e.g., paper ‘shadow charts’ or whiteboards," according to the guide.

Access the guide.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.